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Abstract
Human African trypanosomiasis is a neglected parasitic disease that is fatal if untreated. The current drugs available to
eliminate the causative agent Trypanosoma brucei have multiple liabilities, including toxicity, increasing problems due to
treatment failure and limited efficacy. There are two approaches to discover novel antimicrobial drugs - whole-cell screening
and target-based discovery. In the latter case, there is a need to identify and validate novel drug targets in Trypanosoma
parasites. The heat shock proteins (Hsp), while best known as cancer targets with a number of drug candidates in clinical
development, are a family of emerging targets for infectious diseases. In this paper, we report the exploration of T. brucei
Hsp83 – a homolog of human Hsp90 – as a drug target using multiple biophysical and biochemical techniques. Our
approach included the characterization of the chemical sensitivity of the parasitic chaperone against a library of known
Hsp90 inhibitors by means of differential scanning fluorimetry (DSF). Several compounds identified by this screening
procedure were further studied using isothermal titration calorimetry (ITC) and X-ray crystallography, as well as tested in
parasite growth inhibitions assays. These experiments led us to the identification of a benzamide derivative compound
capable of interacting with TbHsp83 more strongly than with its human homologs and structural rationalization of this
selectivity. The results highlight the opportunities created by subtle structural differences to develop new series of
compounds to selectively target the Trypanosoma brucei chaperone and effectively kill the sleeping sickness parasite.
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Introduction
Human African trypanosomiasis (HAT), better known as
sleeping sickness is a vector-borne disease present in sub-Saharan
Africa, transmitted by Glossina tsetse flies and caused by the
protozoan parasite Trypanosoma brucei [1]. Two subspecies of this
kinetoplastid parasite cause disease in humans and are present
with different geographic distributions, T. b. gambiense and T. b.
rhodesiense. The former is responsible for chronic disease in Western
and Central Africa, while infection by the latter leads to the acute
form present in Eastern and Southern Africa. During the initial
stage of the infection, the Trypanosoma parasite lives and multiplies
in the blood and tissue fluids of its human host, thanks to an
elaborate mechanism for evading the host immune system. The
parasite then invades the central nervous system (CNS) to give rise
to the fatal stage 2 infection, during which the classic clinical
symptoms of HAT occur. Currently, there are five clinically used
treatments, which are prescribed based on the causative species
and the stage of the disease [2,3,4]; however, the toxicity of
existing drugs and inappropriate route of administration limit the
efficacy of the current chemotherapy. Consequently, HAT is one
of the most neglected tropical diseases due to the limited
availability of safe and cost-effective control tools [1,2]. New
methods to treat patients are needed to treat and to eventually
eliminate the disease. Among the potential new drug targets,
molecular chaperones represent an interesting group already
validated in other disease areas. Furthermore, a large number of
inhibitors are already available [5], several of which have been
proved to be effective anti-proliferatives against several parasites in
vitro [6,7,8,9,10].
Among the chaperones, heat shock protein 90 (Hsp90) –
alternately referred to as Hsp83 or Hsp86 because of the variable
molecular weight amongst different orthologues – is a hallmark
of the stress response at the cellular level, and a major component
of the eukaryotic proteome [11]. Its main function is to serve as
a molecular chaperone helping nascent polypeptides avoid
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mis-folding and limiting protein aggregation during thermal stress
[12]. In eukaryotes, key regulatory proteins require Hsp90
assistance as a part of their maturation process and are known
as Hsp90 clients [11]. Not surprisingly, limiting Hsp90 chaperone
function either by genetic or chemical means has been found to
result in a net reduction of functional client proteins within the
cell. This severely impacts cell survival and homeostasis, not to
mention its ability to cope with environmental stress [11]. Several
of the client proteins in humans are over-expressed in cancer cells.
Consequently, development of inhibitors against human Hsp90
(hereafter referred to as Hsp90) has been a highly active field in the
anticancer drug therapy field [5,13,14]. These compounds from
natural and synthetic sources have been found to be effective anti-
proliferatives against cancer cells in vitro [15], with over a dozen
having advanced into clinical trials [16]. Although the compounds
represent diverse chemical scaffolds with unique properties, they
all inhibit the enzymatic ATPase function of the chaperone by
binding the ATP pocket in the N-terminal domain (NTD), which
together with the middle and C-terminal domains define the
highly conserved Hsp90 protein architecture [11]. During its
catalytic cycle, the Hsp90 serves as a molecular clamp, binding
both ATP and client protein at its NTD and middle domains
respectively. The transient dimerization of the NTDs is coupled
with both the ATP hydrolysis and chaperone activity [17]. While
in the resting state, the Hsp90 dimerizes solely via its C-terminal
domain. In addition to a multitude of client proteins, the Hsp90
also binds a cohort of co-chaperones that regulate the closing and
opening cycle [11,17].
Like most eukaryotes, all protozoan parasites feature a Hsp90
orthologue in their genomes. Plasmodium Hsp90 is essential, with
geldanamycin effective at inhibiting parasite growth at sub-
micromolar concentrations [18]. In Trypanosoma and Leishmania
parasites, Hsp83 is implicated in thermally induced stage
differentiation [19]. T. brucei Hsp83 (TbHsp83), the subject of
interest herein, is 59% identical in sequence to human Hsp90a.
This sequence identity increases to over 70% in the N-terminal
ATPase domain, with notable sequence divergence only in a few
short stretches (Fig. S1).
To explore the potential of TbHsp83 as a drug target, we
employed a number of biochemical and biophysical techniques.
Our approach began with the heterologous expression of the
protein and the characterization of its enzymatic activity.
Subsequently, a panel of known Hsp90 inhibitors was screened
against the parasitic chaperone using differential scanning
fluorimetry (DSF), with the results compared to their binding to
the human Hsp90 isoforms. Efficacy of the compounds in
inhibiting T. brucei growth correlated with the biophysical results.
A chemical profile was generated from the screening results,
highlighting chemical scaffolds that bind TbHsp83 more strongly
than its human counterparts as well as those that have equal
affinity for both. Structural analysis shows the binding modes of
some of the more potent ligands, including those effective in killing
the parasite in cellular assays, suggesting the possibility of
developing anti-trypanosomal drug leads against TbHsp83.
Materials and Methods
Protein cloning, expression and purification
The full-length coding region of T. brucei Hsp83 (gene
Tb927.10.10980 - TritrypDB, http://www.Tritrypdb.org/ [20])
was cloned from genomic DNA. Full-length Hsp83 protein (Met1
to Asp704) and NTD (Met1 to Lys213) clones were obtained both
including an N-terminal His6-tag. The two proteins were
expressed and purified as previously described [21]. Briefly, clones
were grown in TB media in a LEX bioreactor system (Harbinger
Biotechnology and Engineering Corp., Ontario, Canada). Over-
night starter cultures were left to grow at 37uC until reaching an
OD600 value around 5, cooled to 15uC, and subsequently induced
overnight with 0.5 mM IPTG. Cells were harvested by centrifu-
gation and the pellets resuspended in 40 ml per liter of culture in
50 mM hepes pH 7.5, 500 mM NaCl, 5 mM imidazole, 5%
glycerol, 1 mM benzamidine and 1 mM phenylmethyl sulfonyl
fluoride (PMSF), then flash frozen in liquid nitrogen and stored in
280uC until needed.
The re-suspended pellets were pretreated with 0.5% CHAPS
and 500 U of benzonase for 40 minutes at room temperature and
cells were mechanically lysed using the M-110EH Microfluidizer
Processor (Microfluidics Corp., MA, USA). The cell lysate was
centrifuged to eliminate cells debris and the cleared lysate was
loaded onto a DE52 anion exchange resin (Whatman, MA, USA)
followed by a 2 mL Ni-NTA (Qiagen, MD, USA). The Ni-NTA
column was then washed with 200 mL of a buffer consisting of
50 mM hepes pH 7.5, 500 mM NaCl, 30 mM imidazole and 5%
glycerol. The protein was eluted with 15 mL of a buffer consisting
of 50 mM hepes pH 7.5, 500 mM NaCl, 250 mM imidazole and
5% glycerol. Following elution, 1 mM EDTA and 1 mM TCEP
were added to the sample. The sample was then incubated
overnight with TEV protease at 4uC to cleave the His6-tag in
10 mM hepes, pH 7.5, 500 mM NaCl and 1 mM DTT. The
imidazole was adjusted to 15 mM and the sample was loaded onto
a pre-equilibrated 2.5 mL Ni-NTA column. The sample was
allowed to bind to the nickel resin for 30 minutes after which the
flow through containing the tag cleaved protein was collected. The
protein was further purified by size exclusion chromatography on
a Superdex 200 (GE Healthcare, NJ, USA) in the case of the full
length protein or a Superdex 75 in the case of the NTD, both
columns equilibrated with a buffer consisting of 10 mM hepes,
pH 7.5 and 500 mM NaCl. The full length TbHsp83 peak
fractions eluted at retention volumes consistent with a dimeric
enzyme and monomeric for the NTD. The proteins were
concentrated in an Amicon Ultra centrifugal filter device
(Millipore, MA, USA) and their identities were confirmed by
SDS-PAGE and mass spectroscopy.
Author Summary
Sleeping sickness, or human African trypanosomiasis
(HAT), is a deadly neglected disease for which new
therapeutic options are badly needed. Current drugs have
several liabilities including toxicity and route of adminis-
tration limiting their efficacy to combat the disease. Our
study aimed at validating a potential new drug target
against Trypanosoma brucei, its heat shock protein 83
(Hsp83). The chaperone was screened against a repur-
posed library composed of inhibitors against the human
Hsp90. The compounds were assayed in their ability to
bind the T. brucei protein and to kill the parasite. Our work
has identified selective and high-affinity chemical com-
pounds targeting the parasitic Hsp83. Additionally, struc-
tural studies were conducted to explore the observed
selectivity of selected inhibitors. Our work has validated T.
brucei Hsp83 as a potential target for future drug discovery
campaigns. It has also shown the strength of repurposing
chemical libraries developed against human proteins,
emphasizing the possibility to piggyback current and past
drug discovery efforts for other diseases in the search for
new drugs against neglected tropical diseases.
T. brucei Hsp83 in Complex with Inhibitors
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ATPase characterization
The malachite green assay was used to characterize the ATPase
activity of T. brucei Hsp83. We determined the amount of
inorganic phosphate produced after incubating 95 nM TbHsp83
full-length 1 h at 37uC with its nucleotide substrate in 50 mM tris-
HCl pH 7.5, 75 mM NaCl and 6 mM MgCl2. The substrate was
evaluated at a concentration range from 1.9 mM to 2 mM. The
kinetic parameters were obtained by fitting initial rate against
substrate concentration using a nonlinear regression algorithm
(SigmaPlot 2000 software; SPSS Inc., Chicago, USA).
Compound synthesis
Many of the Hsp90 inhibitors used in the assays reported herein
were purchased from commercial sources (Supplemental Table
S1), with six compounds commercially unavailable (Fig. 1) and
synthesized using methods already reported in the literature:
compound 1 (6-chloro-9-(4-methoxy-3,-dimethylpyridin-2-ylmethyl)
-9H-purin-2-ylamine (BIIB021) [22]; compound 2 (9-(sec-butyl)-8-
(2,5-dimethoxybenzyl)-2-methyl-9H-purin-6-amine) [23]; compound
3 – (2-amino-4-[2,4-dichloro-5-(2-diethylaminoethoxy)phenyl]thio-
pheno[2,3-d]pyrimidine-6-carboxylic acid ethylamide) [24]; com-
pound 4 (4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetra-
hydro-1H-indazol-1-yl]-2-[(trans-4-hydroxycyclohexyl)amino]ben-
zamide) (SNX-2112) [25]; compound 5 (4-(6,6-dimethyl-4-oxo-3-
(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((2-(methy-
lthio)ethyl)amino)benzamide) [25]; compound 6 (N4-[8-(5-acet-
ylpyridin-2-yl)-8-azabicyclo[3.2.1]oct-3-endo-yl]-2-[(trans-4-hydro-
xycyclohexyl)amino]benzene-1,4-dicarboxamide) [26].
Differential scanning fluorimetry (DSF)
DSF screening was carried out using a LightCycler 480 Real
Time PCR System (Roche Applied Science, Quebec, Canada).
The NTDs from TbHsp83 as well as human Hsp90s a and b were
buffered in 100 mM hepes pH 7.5, 150 mM NaCl and assayed in
a 384-well format. The final concentration of the protein sample
was optimized between 0.05 and 0.2 mg/ml for each NTD
(concentration selected based on pre-testing results to avoid
saturation of the fluorescence detector). The Hsp90 inhibitors
were used at a final concentration of 25 mM (the full list of
compounds is available as supplementary information, Fig. S2).
SYPRO Orange (Molecular Probes, OR, USA) was added as a
fluorescence probe in a dilution of 1:1000. The experiments were
conducted between 20uC to 95uC at a heating rate of 1uC per
minute. The recorded fluorescence reads were fitted to the
Boltzmann sigmoid function using Bioactive software (Harbinger
Biotechnology and Engineering Corp., Ontario, Canada). The
inflection point of each fitted curve is defined as the melting
temperature (Tm). The observed temperature shift, DTm, was
Figure 1. Hsp90 inhibitors. Chemical representation of the compounds co-crystallized with T. brucei Hsp83 NTD and the non- commercially
available compounds used in this study. All the compounds are listed in the supplementary material (Fig. S2).
doi:10.1371/journal.pntd.0002492.g001
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recorded as the difference between Tm of a sample and a reference
in the same plate (i.e. Tm of the protein with ligand minus Tm of
the protein without ligand). Thermal shifts above 2uC were
considered significant.
ITC measurements
ITC experiments were performed using a VP-ITC instrument
(GE healthcare, NJ, USA). Injections of Hsp90 inhibitor solution
were added to sample solutions of TbHsp83 NTD, with
concentrations of 200 mM and 20 mM respectively. Titrations
were conducted at 20uC in 100 mM hepes pH 7.5, 150 mM NaCl
and 0.7% DMSO. The experimental data were fitted to a
theoretical titration curve using the software package Origin
(OriginLab Corporation, MA, USA), with DH (binding enthalpy
in kcal mol21), Ka (association constant) and n (number of binding
sites per monomer), as adjustable parameters. Kd (dissociation
constant) was calculated as 1/Ka. The standard free energy change
and other thermodynamic parameters were calculated using the
equations DG=2RT ln (Ka) and DG=DH2TDS, where DG, DH,
and DS are the changes in free energy, enthalpy, and entropy of
binding, respectively.
Protein crystallization, crystallographic data collection,
structure determination and refinement
A purified sample of the tag-cleaved TbHsp83 NTD was
crystallized using the sitting drop vapor diffusion method in the
presence of three different inhibitors (Fig. 1). All crystals were
obtained by mixing one part of protein solution at 12 mg/ml
(10 mM hepes pH 7.5, 500 mM NaCl, 2 mM TCEP and 4 mM
MgCl2) containing 2 mM inhibitor with one part of reservoir
solution. In the case of compound 1, the reservoir solution
contained 2 M ammonium sulfate, 2% PEG400, 100 mM hepes
pH 7.5; for the thienopyrimidine derivative compound it con-
tained, 25% PEG 3350, 200 mM ammonium acetate and
100 mM hepes pH 7.5; and for the benzamidine derivative it
included, 25% PEG 8000, 200 mM NaCl, 100 mM sodium
cacodylate pH 5.5. Crystals appeared within three weeks and were
cryo-protected in glycerol supplemented mother liquor before
being flash cooled in liquid nitrogen. The diffraction data was
collected using an X-ray source equipped with an R-Axis IV
detector (Rigaku, TX, USA) and processed with HKL2000. The
structures were determined by molecular replacement. The
Leishmania major Hsp83 NTD (PDB code 3H80) served as a search
model for the first complex structure of the T. brucei NTD, which
was used as the model for subsequent structures. Phaser [27,28]
was used for the molecular replacement calculations, while model
building was performed with COOT [29,30] and the structures
were refined with REFMAC5 [31] from the CCP4 suite of
programs [32] and Buster-TNT [33]. Inhibitor coordinates and
geometry restraints were created within the PRODRG topology
server [34]. The stereochemistry of both models was checked by
MOLPROBITY [35]. Relevant data collection and refinements
statistics are shown in Table 1. The coordinates for the structure
Table 1. Summary of crystallographic parameters and model refinement statistics for T. brucei Hsp83 NTD complexes.
Inhibitor Compound 1 Compound 3 Compound 4
Space group P21 P212121 P212121
a (A˚) 55.65 60.04 70.92
b (A˚) 65.81 60.94 72.10
c (A˚) 62.74 126.99 152.15
b 92.3u - -
Resolution range (A˚) 50 – 2.00 (2.03 – 2.00) 35 – 2.15 (2.19 – 2.15) 50 – 2.6 (2.71 – 2.6)
Unique reflections 30581 (16406) 25590 (1252) 24806 (2665)
Redundancy 3.7 (3.4) 6.7 (6.6) 3.7 (3.6)
Rmerge (%) 7.5 (52.8) 7.1 (72.4) 7.1 (37.1)
Completeness (%) 99.3 (93.7) 97.8 (97.1) 99.7 (98.5)
I/s(I) 9.6 (2.4) 12.6 (3.05) 10.4 (2.9)
VM (A˚
3/Da) 2.4 2.2 2.5
PDB code 3O6O 3OMU 3OPD
R-value 0.19 (0.20) 0.22 (0.28) 0.18 (0.23)
Rfree 0.23 (0.26) 0.27 (0.38) 0.24 (0.29)
r.m.s bonds (A˚) 0.010 0.009 0.01
r.m.s angles (6) 1.106 1.236 1.19
Number of atoms
Protein 3229 3108 4629
Organic 54 62 99
Solvent 193 96 359
Ramachandran plot
Favored 426/432 411/421 588/603
Outliers 0/432 0/421 1/603
Average B factors (A˚2) 32.72 41.71 56.35
doi:10.1371/journal.pntd.0002492.t001
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and their structure factors have been deposited with the Protein
Data Bank (http://www.pdb.org [36]).
Structure analysis
Structure superposition were calculated with LSQKAB [37] as
implemented in the CCP4 package. Ligand-protein interactions
were calculated and 2-D plots were generated by LigPlot+ [38].
The structure figures herein were generated with PyMOL
(DeLano Scientific, Palo Alto, California, USA. http://www.
pymol.org).
Parasite growth inhibition assay
Assay conditions for T. brucei 427 cell based assay were followed
as previously reported in the literature [39].
Results
Enzymatic assays
Kinetic constants of the enzymatic activity of TbHsp83 were
determined using the standard malachite green assay. With
Vmax = 3761.6 pmoles P/min (Fig. S3), the ATPase activity of
this parasitic chaperone is weak compared with other ATPases
such as AAA (ATPases Associated with various cellular Activities)
or P-type enzymes, but within the range observed for other Hsp90
proteins [7,40,41]. The Km (360 mM ATP) was also within the
range of values previously determined for other Hsp90 chaperones
from other organisms (Table 2).
Differential scanning fluorimetry (DSF)
The DSF assay results for TbHsp83, Hsp90a and Hsp90b in the
presence of known or putative Hsp90 inhibitors are shown in a bar
graph for NTD binders (Fig. 2A) and as a heat map for all the
compounds tested (Fig. S2). Clearly, a number of compounds bind
TbHsp83 with different levels of affinity, generating a chemical
fingerprint (Fig. 2A). Furthermore, screening the human homo-
logues as controls generated different fingerprints indicative of
differences in chemical sensitivity between the parasite and human
chaperones that might be exploited in the design of selective
inhibitors. In particular, macbecin, geldanamycin and derivatives
[6], and compound 5 demonstrated markedly stronger binding to
TbHsp83, whereas radicicol and NVP-AUY922 had stronger
affinity for human Hsp90. Overall, this experiment demonstrated
the potential for designing parasite-specific inhibitors.
Isothermal titration calorimetry (ITC)
As a secondary assay, some of the compounds were tested with
TbHsp83 using isothermal titration calorimetry. All the interac-
tions measured were exothermic and enthalpy driven (Fig. 2B).
Most of them displayed positive entropic contributions, with the
exception of the interaction between the parasitic chaperone and
compound 1 with a negative entropic term (DS=235.6 kcal/
mol). This interaction was also significantly more exothermic than
the others suggesting an enthalpic compensation. Most of the
measured interactions showed high affinity, with Kd values in the
nanomolar range (Table 3), compounds 1 and 4, CAY10607 and
NVP-AUY922 displayed sharp transitions curves in the binding
enthalpies which could lead to an underestimation of the affinity
(Fig. S4). Also the ITC derived affinities could have been affected
in other compounds as visualized by poor baseline in the binding
thermograms for compounds 2, 4, 5 and geldanamycin; and,
molar rations higher than 1 for 17-AEP-GA, Macbecin I and
NVP-AUY922. The compromised results were caused by limited
solubility of some of the tested compounds and protein precipi-
tation during the ITC experiments. But, the reported values
represent the best values obtained from multiple repetitions.
Furthermore, the Kd derived values are in agreement with
previously reported affinities even in the case of compromised
ITC measurements such as the one reported for NVP-AUY92
(Table 3). The highest affinity recorded for the Trypanosoma
chaperone was in the low nanomolar range (Kd = 2.8 nM for a
benzamide derivative, compound 4). As stated above, the recorded
affinities were similar - within the same order of magnitude - to
previously reported ITC measurements of Hsp90 from other
species (Table 3) [42,43,44,45,46,47]. The only exception was the
2.5 fold higher affinity displayed by T. brucei Hsp83 for macbecin I
when compared to the Kd value reported for the yeast counterpart
[45]. The ITC experiments generally corroborated and validated
the DSF results (Fig. S5), and also provided thermodynamic
insights about the interaction between TbHsp83 and the
inhibitors.
Parasite growth inhibition assays
Several of the compounds characterized using DSF and ITC
assays were evaluated for their ability to kill T. brucei in a
continuous in vitro culture system. Five out of the six compounds
tested showed EC50 against the blood stream stage of T. brucei 427
in the submicromolar range (Table 3). The outlier compound,
namely compound 2, also showed a non-significant DTm on
TbHsp83 and the lowest affinity measured by ITC, consistent with
correlation between binding affinity and in vitro efficacy (Fig. S5),
although more data would be needed to corroborate the
correlation.
Crystallography
We have crystallized the N-terminal domain of Hsp83 from
T. brucei in complex with three different synthetic inhibitors –
compounds 1, 3 and 4 (Fig. 3 & 4), but did not succeed in
generating crystals of high acceptable diffraction quality in apo
form or bound with ADP or ATP analogues. In general, the
TbHsp83 crystals obtained were sensitive to the cryo-protection
buffer and harvesting techniques. All the complex crystals were
obtained by co-crystallization of the parasitic chaperone and the
inhibitors. Two out of the three crystals belonged to the same
space group but each one had unique cell parameters. Two of the
Table 2. ATPase kinetic parameters for T. brucei Hsp83 and reported activities for other Hsp90s*.
T. brucei Human Hsp90b [40] Yeast [41] P. falciparum [7]
Km (mM) 358634 840660 510670 611
kcat (s
21) 0.12 0.00165
Vmax (mM Pi s
21) 1.13610226461024
(*) values 6 standard deviation.
doi:10.1371/journal.pntd.0002492.t002
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crystals, thienopyrimidine (compound 3) and benzamide (com-
pound 4) complexes, belonged to the orthorhombic system,
containing two or three non-crystallographic symmetry (NCS)
related complexes per asymmetric unit (ASU) respectively. The
other crystal (compound 1 complex) was a primitive monoclinical
with two copies per ASU. Despite these variations in space groups
and cell parameters, no significant differences were observed
between the three crystal forms in solvent content (VM values in
Table 1) and most of the lattice contacts were shared. Extensive
crystal contacts included an anti-parallel arrangement of the 1st
and last b strands. Additional contacts included the loop regions
connecting a helices 1 and 2, and helices 4 and 5.
Overall, the structure of the NTD of TbHsp83 was similar to
previously determined Hsp90 nucleotide-binding domains (Fig. 3).
The electron density in all three complexes was well defined for
the whole polypeptide chain, facilitating the modeling of almost all
of the cloned residues with the exception of the last few at the
C-terminus. The final models showed good stereochemistry
Figure 2. Thermal shift assay results and thermodynamic parameters of T. brucei Hsp83 NTD interactions with inhibitors. (A) The DTm
values obtained by DSF are presented in this bar representation for a subset of the Hsp90 inhibitors tested. The DSF results for all compounds tested
are available as supplementary material. (B) Binding Interactions Average values for DG, DH, -TDS are given for protein-compound interactions
measured by ITC. The DTm values derived from DSF studies are also indicated. The raw ITC graphs are available as a supplementary material.
doi:10.1371/journal.pntd.0002492.g002
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parameters. The resolution allowed us to explicitly model a
significant number of solvent molecules. Also the electron density
was unambiguous for the three different inhibitors present in each
crystal form and for each molecule in the ASU (Fig. S6). Due to
the absence of an apo Trypanosoma structure we compared it with a
Leishmania Hsp90 in complex with AMPPNP and ADP also
determined by our group (PDB codes 3H80 and 3U67, Hills et al.,
unpublished results). The structural differences observed between
each complex and this previously determined parasitic Hsp90
were linked to the nature of the inhibitor bound to the nucleotide
binding site and not to any Trypanosomes’ specific structural
features. Additionally, the structural superposition between each
T. brucei Hsp83 complex to each other showed that each
compound induced specific structural rearrangements because
superposition of non-crystallographic symmetry (NCS) related
molecules revealed lower r.m.s.d values than those obtained when
superposing molecules with different inhibitors bound (Table 4).
Structural analysis of TbHsp83 NTD complexes
TbHsp83-compound 1 complex. Compound 1 (commonly
known as BIIB021) is a rationally designed Hsp90 inhibitor
derived from a purine backbone [22]. It is composed of a modified
halogenated purine moiety linked to a pyrimidyl ring (Fig. 1). The
compound was slightly bent by T. brucei Hsp83 NTD to adopt an
angle of,100u between the planes of the purine ring and pyrimidyl
rings (Fig. 5). The purine moiety showed a hydrogen-bonding
pattern already seen in the adenosine-binding pocket in other
Hsp90 structures in complex with ADP or ATP mimetics (Fig. 4).
The N6 (adenosine numbering scheme) was hydrogen-bonded to
the dO1 of Asp78 and N1 to the cO of Thr169. Conversely, the
pyridyl group occupied a modified phosphate binding pocket not
seen in the nucleotide bound structures and dominated by non-
polar interactions, including an aromatic p-stacking interaction
between the pyridyl ring and the side chain of Phe123 (Fig. 4 & 5).
The modified phosphate-binding pocket was composed of the
following residues Met83, Leu92, Phe123, Tyr124, Val135 and
Trp147. The elongation of helix-3 at its C-terminus joining with
helix-4 into a single helix, created this modified pocket. Two
residues, Asn90 and Asn91, shifted significantly their position by
over 3 A˚ in their Ca atoms, when compared to the other TbHsp83
NTD complexes with inhibitors (Fig. 6). This movement displaced
Leu92 outwards. Other regions that shifted to create pocket 2 were
around residues Val135 and Trp147 (Fig. 4 & 5). These residues
were in the b-sheet floor of the ATP binding site, in strands 4 and 5
that also moved outwards to accommodate the pyridyl ring.
Identical structural rearrangements have been observed in the
recently deposited complex between human aHsp90 NTD with
compound 1 (PDB 3QDD). The r.m.d.s between the human and
Trypanosoma complexes is 0.67 A˚ for a Ca superposition. More
specifically, compound 1 adopts the same conformation and
interacts with equivalent residues in both structures (Fig. 3A and
S7). The similar structural changes correlate with our DSF assay
Table 3. T. brucei Hsp83 NTD affinity* and parasite growth inhibition measurements.
Trypanosoma brucei Human Previous ITC measurements
Compound DTm (6C) Kd (mM) S.D. EC50 (mM) DTm (6C) Kd (mM) S.D Ref.
AMPPNP 0.3 N.D. 141 _ b [42]
N.D. 111 6 6.4 d [46]
AMPPSP N.D N.D. 109 6 42 c [44]
ADP 0.1 N.D. 0.3a 0.5b 15 _ b [42]
N.D. 35 6 3.7 c [44]
Geldanamycin 14.8 1.000 6 0.246 0.013 [6] 2 4.3 2.9 6 0.32 d [46]
17-AEP-GA 13.8 0.714 6 0.034 5.1 4.2
17-AAG-GA 10.7 N.D. 0.038 [6] 3.1 1.6 0.3 6 0.06 a [47]
17-DAMG-GA 11.7 N.D. 0.003 [6] 5.5 3.9 0.35 6 0.04 b [42]
Macbecin I 16.9 0.093 6 0.010 10.2 8.6 0.24 6 0.03 d [45]
Radicicol 6.5 N.D. 0.070 [6] 18.8 15.6 0.00004 _ a [47]
N.D. 0.00015 _ b [47]
N.D. 0.025 6 0.0004 c [44]
N.D. 0.016 6 0.00003 d [46]
NVP-AUY922 18.5 0.003 6 0.001 22.3 19.6 0.0017 6 0.0005 c [43]
CCT018159 8.01 4.975 6 0.678 12.1 7.5 _
CAY10607 13.3 0.010 6 0.001 15.3 12.1 _
Compound 1 10.5 0.009 6 0.002 0.31 12.0 8.7 _
Compound 2 0.8 9.260 6 3.430 13 1.2 20.5 _
Compound 3 12.7 0.026 6 0.009 0.21 14.7 12.9 _
Compound 4 15.5 0.003 6 0.001 0.10 17.0 15.1 _
Compound 5 12.03 0.794 6 0.604 0.13 2.3 0.4 _
Compound 6 10.4 N.D. 0.22 8.5 4.9 _
(*)Affinity measurements by ITC and DSF methods are reported.
a) Human Hsp90a; b) Human Hsp90b; c) Human TRAP-1; d) Yeast Hsp83. N.D. – not determined.
doi:10.1371/journal.pntd.0002492.t003
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data – compound 1 stabilized both the human and parasite proteins
(Table 3 and Fig. 2A). Furthermore, they highlight the plasticity of
the ATP binding domain of Hsp90 and how the conformational
changes are ligand induced.
TbHsp83-compound 3 complex. The thienopyrimidine
derivative compound 3 is a very potent human Hsp90 inhibitor
identified by means of a fragment-based approach to generate
novel chemical scaffolds [24]. Based on our assays, this is also a
potent inhibitor of TbHsp83. The molecule is composed of a
central di-halogenated phenyl ring, linked to a thienopyrimidine
moiety at its position 1 and an alkyl group at position 5 (Fig. 1).
The thienopyrimidine moiety occupies pocket 1, in a similar
arrangement as the purine moiety of compound 1. But its
carboxamide modification establishes additional hydrogen bonds
with the enzyme; a direct one with residues Gly82 and two water-
mediated with residues Lys44 and Asn91. The additional
interactions extend the boundaries of this pocket outside the strict
adenosine-binding site. But unlike compound 1 and the benza-
mide derivative compound 4, it shares several contacts with ATP,
like Asn91 a hydrogen-bonding partner of the ribose moiety
(Fig. 4). Additional common residues include, Asn36, Gly120 and
Phe124 positioned to stabilize the c-phosphate of ATP. Water
molecules mediate the interactions between these protein residues
and the thienopyrimidine derivative, distinct from the phospho-
nucleotide where they contact directly the phosphate group. The
halogenated aromatic ring is positioned against the protein at the
entrance of pocket 2, with only a chlorine atom occupying it. Its
aliphatic diethylamino-ethanol substituent is mostly solvent
Figure 3. Crystal structure of T. brucei Hsp83 NTD. (A) A cartoon representation of the parasitic protein, the nucleotide lid region is highlighted
in magenta, a-helices 3 and 4 are shown in light green. The ATP mimetic shown to indicate the position of the nucleotide binding site was derived
from the L. major complex structure (PBD entry 3H80). (B) NTDs structural overlay between TbHsp83 (cyan) and human aHsp90 (yellow – PDB entry
3QDD). (C) Structural overlay of TbHsp83 NTD inhibitor complexes. Two orthogonal views of ribbon representations of the three complexes and the
compounds are indicated as sticks. The structures are colored as follows, compound 1 complex – cyan; thienopyrimidine derivative compound 3 –
green; benzamidine derivative compound 4 – brown.
doi:10.1371/journal.pntd.0002492.g003
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exposed and its interaction with the chaperone was water-
mediated hydrogen bonds, to Asn36 and Phe123. The position
of Asn91 was different when compared to the other two
complexes, in this case the side chain makes a direct contact with
the small molecule in a conformation expected in the complex of
Hsp90 with phosphonucleotides. A major structural characteristic
of this complex is the modification of helices 3 and 4, each
shortened by a couple of residues. The unwinding of helix 3 and 4
pushes the position of the latter closer to helix 1, shifting its
position by over 1 A˚ (Fig. 6).
TbHsp83-compound 4 complex. The benzamide derived
compound 4 was identified through a chemogenomics approach
coupled to lead optimization to produce a highly selective and
orally active Hsp90 inhibitor for cancer treatment [48]. As seen in
the compound 3 complex, the benzamide ring occupies the purine
pocket in the same way as the natural nucleotide and establishes
similar polar contacts as the other two T. brucei Hsp83 inhibitors.
The modified dihydroindazolone group occupies the pocket 2 but
unlike the previous compounds a hydrogen bond was observed
with Tyr124 (Fig. 4). In addition to the polar interaction, the
presence of an electronegative trifluoromethyl group creates a
smaller phosphate binding pocket resulting in a tight packing
between the compound and the protein, when compared with that
seen in the TbHsp83-compound 1 NTD complex (Fig. 7). Other
polar interactions through a water molecule were observed
between the pyrazole ring and residues Asn36 and Gly120,
Figure 4. Protein-ligand interaction maps of T. brucei Hsp83 NTD complexes. The Hsp83 NTD-AMPPNP interaction map was derived from
the L. major complex structure (PDB entry 3U67). The gray region represents the adenosine binding pocket; additional residues in common with the
nucleotide analogue complex structure are highlighted in blue.
doi:10.1371/journal.pntd.0002492.g004
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similar to those observed with the thienopyrimidine derivative
complex. Both compounds appear to exploit this water molecule
that mimics the position of one of the phosphate groups of ATP.
The largest structural rearrangement observed in this complex was
the flipping in of Asn91 side chain that created a disruption at
beginning of the helix-4. The new position of Asn91 side chain was
stabilized by a polar interaction with the indole nitrogen of
Trp147. This interaction is an important step to narrowing pocket
2. The tilted position of helix-4 moving towards the binding pocket
also affected the secondary structure at helix-4 C-terminus
changing from compact turns observed in the other two complexes
to extended b-bridges. Overall these structural rearrangements
create a closed pocket that occludes most of the inhibitor from the
solvent (Fig. 4 & 6). All complex TbHsp83-inhibitor complex
crystallographic structures displayed unique structural features
emphasizing the malleability of the chaperone nucleotide-binding
domain.
Discussion
From our results, the ATPase activity of the Trypanosoma
chaperone is within the range of measured activities for this class of
enzymes, which are characterized by a rather low turnover and
high Km values (Table 2) [17]. In comparison with previously
reported enzymatic constants the T. brucei chaperone has a slightly
higher affinity for its substrate [7,40,41]. Lower Km values have
also been reported for other Hsp90s, albeit at a lower incubation
temperature 25uC [17]. In addition to the low affinity for its
substrate, Hsp90 and its homologues tend to have slow turnover
rates, ranging from 0.0001 to 0.02 s21 [17]. Nonetheless, the T.
brucei chaperone has a ten-fold higher turnover rate together with a
higher affinity, which makes for a more efficient ATPase. There is
no clear explanation for this enhanced ATPase activity but a
similar observation has also been made for Plasmodium falciparum
Hsp90 [7], another human parasite. This is an interesting trend to
be evaluated as new activity reports from parasitic chaperones
become available. A tantalizing hypothesis is that parasites might
rely more heavily on their Hsp90 chaperones to maintain cellular
homeostasis by stabilizing key cell regulators under hostile
conditions. An observation that would be consistent with human
Hsp90’s pivotal role in some forms of cancer [49] (leading to its
label as the Achilles’ heel of malignant cells), a role that could also
be exploited to treat parasitic infections [18]. Finally, a role has
been determined for this chaperone in Candida albicans in the
resistant phenotypes against commonly used antifungal drugs,
then a plausible hypothesis could be that the parasitic hyperactive
Hsp90 could facilitate the emergence of drug resistant parasites
[50,51].
Previous studies have determined the sensitivity of several
parasitic chaperones to known inhibitors, such as geldanamycin
Table 4. Structural superposition of T. brucei Hsp83 NTD complexes.
Compound 1 Compound 3 Compound 4
A B A B A B C
Compound 1 A _
B 0.73* _
Compound 3 A 1.13 0.75 _
B 1.04 0.96 0.53 _
Compound 4 A 1.13 0.85 0.97 1.13 _
B 0.97 0.76 0.88 1.02 0.64 _
C 0.99 0.77 0.92 1.04 0.64 0.37 _
(*) Root mean square deviation (r.m.s.d.) values in A˚ for all atoms superposition (residues 1 to 206). R.m.s.d. between non-crystallographic symmetry (NCS) mates is
shown in italic.
doi:10.1371/journal.pntd.0002492.t004
Figure 5. Complex structures of T. brucei Hsp83 and inhibitors. Protein-ligand interactions are depicted between the inhibitory compound
and protein residues, indicated as sticks, the protein backbone is shown as a Ca trace. The structures are colored as follows, compound 1 complex –
cyan; thienopyrimidine derivative compound 3 – green; benzamidine derivative compound 4 – brown.
doi:10.1371/journal.pntd.0002492.g005
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and radicicol, and their deleterious effects on parasite growth
[6,7,8,9,10,52,53]. To identify and characterize inhibitors of
TbHsp83, we used the DSF technique to screen a collection of
near 40 compounds described in the literature as known or
putative Hsp90 binders. The bulk of the collection includes ATP-
competitive inhibitors predicted to bind the N-terminal region but
also several putative C-terminal inhibitors. Initially, our DSF
assays were performed with both full-length proteins and
individual domains and two observations were derived from these
experiments.
In the case of the human Hsp90s, there appears to be a similar
DTm for both the N-terminal domain and the full length protein,
Figure 6. T. brucei Hsp83 NTD structural changes. Cartoon representation of a-helices 1, 3 and 4, and the lid region from the Hsp83 in complex
with different compounds (compound 1 complex – cyan; thienopyrimidine derivative compound 3 – green; benzamidine derivative compound 4 –
brown; and L. major with AMPPNP – magenta). Side chains of residues Asn90 and Asn91 are indicated in sticks, also the nucleotide is indicated as
yellow dots to illustrate the location of binding site.
doi:10.1371/journal.pntd.0002492.g006
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whilst in the case of the T. brucei Hsp83, the DTm appears to be
greater for the N-terminal domain, with a significantly weaker shift
for the full length protein. The T. brucei C-terminal domain, the
middle domain and the combined C-terminal & middle domain
were also tested and did not show any significant DTm, as would
be expected for compounds which bind in the N-terminal ATP
binding site (Fig. S2). Taken together, these observations suggest (i)
the compounds interact primarily with the N-terminal ATPase
domain, as most of the them are known to do with other Hps90
proteins; (ii) the DSF assay is an effective technique for identifying
potential Hsp90 inhibitors; (iii) we can focus on the N-terminal
ATPase domain for characterizing and optimizing inhibitors of
TbHsp83.
We observed an inverse relationship (R2 = 0.88) existed between
ITC-derived Kd values and DSF-derived DTm values, with the
caveat that some of the ITC reported affinities might be under or
overestimated affecting the correlation between the two assays
(Fig. S5). Such a relationship has been reported for other proteins
such as protein kinases [54] and bromodomains [55], but with
even higher correlation coefficients. The observed correlation
would likely be greater if the tested compounds were structurally
related because the correlation is stronger for compounds sharing
a common binding mode. By virtue of its operating principles, the
DSF method is particularly sensitive to entropy-driven binding
[56]. Therefore, when contributions of enthalpy and entropy are
different, change in DTm may not correspond to Kd [57,58,59].
The lower detection limit of our thermal shift assay is in the
micromolar range when using a compound concentration of
25 mM (e.g., compound 2 with DTm = 0.8uC and Kd = 9.3 mM.).
The observed limit explains the absence of hits for the C-terminal
domain since they have been known to bind with low affinity
(1023 to 1026 M range). Nonetheless, our approach has been
successful in identifying high affinity binders by screening a narrow
set of Hsp90 inhibitors rather than a broad diverse library. Our
results support the DSF assay as a suitable technique to screen
chemical libraries originally designed against human targets, as we
screened compounds originally designed as anti-human Hsp90
inhibitors.
The three-dimensional structure of the NTD of T. brucei Hsp83
in complex with three different inhibitors showed the large degree
of structural flexibility of the chaperone. As was previously
described, the nucleotide-binding site can be divided into the
adenosine and the phosphate binding pockets [25]. All the
inhibitors described here occupy both pockets but differ in how
they expand or modify these binding cavities [60,61,62]. All of the
inhibitor scaffolds recapitulate the adenosine mode of binding to
the chaperone (Fig. 4 & 5). Previous structures have established
that the base is recognized by its Watson-Crick face generating two
hydrogen bonds with the NTD; one is a water-mediated
interaction while the other one is between the base amino group
and the side chain of a well conserved aspartic acid residue (Asp78
in T. brucei). All of the inhibitors described here preserve these
interactions, including the water mediated one. Interestingly, the
nucleotide-binding site of the NTD is highly conserved among
different Hsp90 family members, with the exception of Ile171
(located in the region of sequence divergence highlighted in orange
in Fig. S1) being a moderately variable position located at the
bottom of the adenosine-binding pocket (Fig. S8). This side chain
is in contact with residue Leu34 and indirectly with Ile35, a pair of
residues directly implicated in resistance to the natural product
radicicol [46]. This observation could rationalize the significant
differences measured by our DSF assay between the TbHsp83 and
the human a and b Hsp90s with respect to radicicol. It also
highlights the large impact that small sequence differences could
have in the chemical sensitivity of the parasitic chaperone.
The thienopyrimidine derivative, namely compound 3, was the
only compound to establish charged contacts in the periphery of
the adenosine binding pocket with residues involved in the
interaction with the sugar moiety of the phosphonucleotide, such
as Asn91, while the other two compounds engaged these residues
in non-polar interactions (Fig. 4 & 5). As a result, this region
located at the end of helix-3 between residues 87 to 93 showed the
largest structural differences among the three complex structures
with values exceeding 4 A˚ r.m.s.d. for the main chain atoms of
residues Asn91 and Asn92 (Fig. 6). This structural rearrangement
tilted the position of helix 4, a key structural element in the NTD,
because together with helix 5 it composes the lid region. The
closing of the lid over the ATP during the catalytic cycle is a
preliminary step also linked to the dimerization of the NTDs, as it
allows the movement of helix 1 and facilitates the exchange of the
N-terminal b-strands among interacting NTDs. On the basis of
the large structural movements displayed during the ATPase cycle
of Hsp90, we propose the region located at the end of helix 3 plays
an important role as a sensor for the binding of nucleotides a
function facilitated by its structural plasticity and highlighted by
recent NMR studies of the Hsp90 [63]. In our case, the region of
structural flexibility allows the NTD to accommodate a diverse set
of compounds generating unique binding regions for each one.
The uniqueness of the conformations induced by each compound
to the region encompassed by residues 87 to 93 has extensive
repercussions in the lid position. Each complex structure showed a
unique open conformation of the lid region (Fig. 6) with the
Figure 7. T. brucei Hsp83 nucleotide binding pocket. Surface representation in the NTD binding site for the Trypanosoma complex structures
(compound 1 complex – cyan; thienopyrimidine derivative compound 3 – green; benzamidine derivative compound 4 – brown). The nucleotide
binding pocket of L. major (PDB code 3H80 – Magenta) is shown for comparison purposes.
doi:10.1371/journal.pntd.0002492.g007
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subsequent impact on the phosphate-binding pocket (Fig. 7). This
structural flexibility was already described for the NTD when
binding both substrate and inhibitors and two main conclusions
can be drawn from these observations. First, due to the large
structural rearrangements involved upon inhibitor association, the
contribution from regions other than the nucleotide-binding
pocket can be quite substantial and hard to predict by analyzing
the structure alone. Second, the cellular effects of Hsp90 inhi-
bitors are related to the conformational limitations imposed
on the chaperone, affecting co-chaperone binding and long-
range coupled motions observed between the NTD and CTD
domains [64].
Compound 5 preferentially binds TbHsp83 with high affinity
but not human Hsp90, but did not yield diffracting crystals in our
attempts. Therefore, we are unable to provide a definitive
structural explanation for this benzamide’s selective behavior.
We also cannot utilize existing human Hsp90 structures and our
TbHsp83 structures for this purpose because, as explained above,
the chaperone’s flexibility allows it to be reshaped differently by
different classes of inhibitors. The chemical selectivity of
compound 5 suggests that it uniquely recognizes the difference
between the flexibility the parasite and human chaperones.
Remarkably, the differentiation is a product of one or more of
the three short regions of sequence divergence shown in Fig. S1.
This study presents a detailed structural and chemical
characterization of TbHsp83 as a potential drug target against
African trypanosomiasis a fatal neglected disease. We have
identified a chemical scaffold with a preference for the Trypanosoma
chaperone over its host counterpart. Furthermore, the assayed
compounds were able to inhibit the growth of the parasite in vitro in
a manner that correlate strongly to their binding affinities to
TbHsp83, validating this parasite chaperone as a potential target
to combat sleeping sickness. Target validation and early lead
identification represent the initial stages of a potential drug
development program. Furthermore, in the Hsp90 case, there is
the possibility of taking advantage of the much more advanced
anti-Hsp90 programs in the cancer field. We believe that tapping
into other therapeutics areas such as cancer might have a great
value in the development of drugs against neglected tropical
diseases.
Generally speaking, a potential weakness in repurposing
compound libraries designed against human targets to search for
anti-parasitic compounds is that the starting chemical points are
not selective. What is important, however, is to show the possibility
of differentiating structure activity relationship between the human
and parasite enzymes. In spite of the high degree of sequence
identity with the human homologue, we have found such a
chemical differentiator for the NTD of TbHsp83 in compound 5
and a number of other analogues. More research is required to
substantiate and elaborate on our hypothesis that this selectivity is
a result of differences in the flexibility of the human and parasite
chaperones.
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